Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA Expands Use of Targeted Therapy for Most Common Leukemia in Adults
The FDA this week approved pirtobrutinib (Jaypirca®) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in ad…
News
FDA Approves First CAR T-Cell Immunotherapy for Marginal Zone Lymphoma
Liso-cel (Breyanzi®) is now approved to treat five types of blood cancer
News
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Data from Master Clinical Trials—focused on transforming care for patients with acute myeloid leukemia—will be presented at ASH.
News
FDA Approves Targeted Immunotherapy for Adults with Follicular Lymphoma
“Although we are making great progress in treating follicular lymphoma, it remains incurable, and we need new treatments like epcoritamab in this chem…
News
FDA approves new drug to treat advanced AML in adults
Blood Cancer United® funding supported menin inhibitor drugs, including ziftomenib, at every stage of scientific development.
News
FDA Approves Drug for People With Advanced Disease Multiple Myeloma
Belantamab mafodotin (Blenrep) in a three-drug combination is now approved for the treatment of relapsed/refractory multiple myeloma.
News
TAP Biotech Partner ImCheck Therapeutics to be Acquired by Ipsen in €1B deal
Ipsen and ImCheck Therapeutics announced they have entered into a definitive agreement in which Ipsen will acquire ImCheck Therapeutics, a private Fre…
Research
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
LUND, SWEDEN, April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and devel…
Research
BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma
Lund, Sweden – March 20, 2025 – BioInvent International AB (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of nov…
